T. Rowe Price Associates’s Sana Biotechnology SANA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.98M | Sell |
2,557,825
-96,313
| -4% | -$263K | ﹤0.01% | 1197 |
|
|
2025
Q1 | $4.46M | Sell |
2,654,138
-454,479
| -15% | -$764K | ﹤0.01% | 1284 |
|
|
2024
Q4 | $5.07M | Buy |
3,108,617
+219,498
| +8% | +$358K | ﹤0.01% | 1283 |
|
|
2024
Q3 | $12M | Sell |
2,889,119
-228,877
| -7% | -$952K | ﹤0.01% | 1105 |
|
|
2024
Q2 | $17M | Sell |
3,117,996
-577,463
| -16% | -$3.15M | ﹤0.01% | 995 |
|
|
2024
Q1 | $37M | Buy |
3,695,459
+101,434
| +3% | +$1.01M | ﹤0.01% | 805 |
|
|
2023
Q4 | $14.7M | Sell |
3,594,025
-3,432,116
| -49% | -$14M | ﹤0.01% | 1019 |
|
|
2023
Q3 | $27.2M | Buy |
7,026,141
+1,902,713
| +37% | +$7.36M | ﹤0.01% | 841 |
|
|
2023
Q2 | $30.5M | Buy |
5,123,428
+612,642
| +14% | +$3.65M | ﹤0.01% | 828 |
|
|
2023
Q1 | $14.8M | Buy |
4,510,786
+246,294
| +6% | +$805K | ﹤0.01% | 992 |
|
|
2022
Q4 | $16.8M | Buy |
4,264,492
+623,989
| +17% | +$2.46M | ﹤0.01% | 958 |
|
|
2022
Q3 | $21.8M | Buy |
3,640,503
+748,922
| +26% | +$4.49M | ﹤0.01% | 877 |
|
|
2022
Q2 | $18.6M | Buy |
2,891,581
+841,448
| +41% | +$5.41M | ﹤0.01% | 1186 |
|
|
2022
Q1 | $16.9M | Buy |
2,050,133
+845,437
| +70% | +$6.98M | ﹤0.01% | 1270 |
|
|
2021
Q4 | $18.6M | Buy |
1,204,696
+17,587
| +1% | +$272K | ﹤0.01% | 1302 |
|
|
2021
Q3 | $26.7M | Sell |
1,187,109
-3,090
| -0.3% | -$69.6K | ﹤0.01% | 1223 |
|
|
2021
Q2 | $23.4M | Sell |
1,190,199
-16,511
| -1% | -$325K | ﹤0.01% | 1263 |
|
|
2021
Q1 | $40.4M | Buy |
+1,206,710
| New | +$40.4M | ﹤0.01% | 1075 |
|